Basel, Switzerland | February 2021
Dr. Marc Lang, PhD joins SpiroChem as a scientific advisor.
Not only SpiroChem is home to the elite of chemists, with the ability to efficiently solve problems in the lab, but we also have the support of a strong network of seasoned scientific advisors with a track record of success.
Marc Lang will join Erick Carreira, Ben Perry and David Sarlah to bring a vast medicinal chemistry expertise to SpiroChem. Marc has decades of experience in many fields of discovery and in particular on antibiotics, antivirals, and oncology. He was Executive Director of the Medicinal Chemistry Unit for Oncology of Novartis in Basel, and a member of the Global Oncology Decision Board at Novartis Institute for Biomedical Research. During his career, he contributed to three compounds currently on the market: Femara®(aromatase inhibitor); Reyataz® (HIV-protease inhibitor); Tasigna® (Bcr/Abl kinase inhibitor); and several promising compounds in clinical trials.
The interdisciplinary scientific advisory board of SpiroChem will play an instrumental role in supporting the continued success of SpiroChem’s medicinal chemistry discovery services. Stay tuned for more announcements!
